Literature DB >> 3402103

Induction of autoimmunity with dendritic cells: studies on thyroiditis in mice.

S C Knight1, J Farrant, J Chan, A Bryant, P A Bedford, C Bateman.   

Abstract

The initiation and maintenance of thyroid autoimmunity by professional antigen-presenting cells were assessed by observing thyroiditis and induction of IgG antibodies to thyroglobulin (Tg). Dendritic cells (DC) were purified from spleens of CBA mice and T cells removed with anti-Thy 1 and complement. Some DC were pulsed with 25-500 micrograms/ml of mouse Tg in vitro and normal syngeneic mice received injections of 10(5) cells intravenously. In untreated animals only 1 thyroid out of 40 showed a lymphocyte infiltrate and antibody to Tg was rarely seen. In animals receiving normal DC without Tg, lymphocyte infiltration was seen 2-6 weeks later in 5 out of 33 thyroids and some animals produced low levels of antibody to thyroglobulin (8 of 33 animals). DC pulsed with 500 micrograms Tg/ml in vitro caused thyroid infiltration in 6 out of 15 animals but did not increase the incidence of anti-Tg antibodies. Lower doses had no effect. When 10(5) DC were given from animals with experimental allergic thyroiditis (EAT, induced with Tg in complete Freund's adjuvant, CFA) more than half of the recipient animals showed thyroiditis (8 out of 15) and autoantibody production (12 of 15 animals). DC may therefore play a role in the initiation and maintenance of autoimmunity by providing a stimulus for antigen-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402103     DOI: 10.1016/0090-1229(88)90021-9

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  17 in total

1.  Monocyte-derived dendritic cells: a potential target for therapy in multiple sclerosis (MS).

Authors:  M E Duddy; G Dickson; S A Hawkins; M A Armstrong
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 2.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

3.  A delayed-type hypersensitivity skin-test system using the insulinoma cell line RINm5F to monitor beta cell-specific cellular autoimmune reactivity in the spontaneously diabetic BB/O rat.

Authors:  H A Voorby; P H Jeucken; H A Drexhage
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

4.  Class II antigens on dendritic cells from the synovial fluids of patients with inflammatory arthritis.

Authors:  S C Knight; P Fryer; S Griffiths; B Harding; J Dixey; B Mansell
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

5.  Maturation of dendritic cells by necrotic thyrocytes facilitates induction of experimental autoimmune thyroiditis.

Authors:  H S Li; P Verginis; G Carayanniotis
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

6.  Thyroid autoantigens and human T cell responses.

Authors:  N Fukuma; S M McLachlan; B Rapoport; J Goodacre; S L Middleton; D I Phillips; C A Pegg; B Rees Smith
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 7.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

8.  Marked dendritic cell-T cell cluster formation in the pancreatic lymph node of the non-obese diabetic mouse.

Authors:  M Clare-Salzler; Y Mullen
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

9.  Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer.

Authors:  M J Clare-Salzler; J Brooks; A Chai; K Van Herle; C Anderson
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.

Authors:  S Homma; Y Sagawa; M Ito; T Ohno; G Toda
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.